Urologists emphasized the importance of AUA guidelines, patient context, and clinical judgment in managing low-grade UTUC. Challenges in diagnosis and treatment include obtaining adequate biopsies and ...

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC ...

Panelists discuss how BCG-unresponsive bladder cancer is defined by disease persistence/recurrence within 6 to 12 months of adequate BCG therapy. Treatment options ...

WNT9B gene mutations significantly increase prostate cancer risk, with a 2- to 12-fold elevation observed across multiple studies. Specific variants, WNT9B E152K and Q47R, show significant ...

Panelists discuss how low-risk non–muscle-invasive bladder cancer (NMIBC) requires transurethral resection of bladder tumor (TURBT) with surveillance. Intermediate-risk disease needs adjuvant ...

This video segment discusses patient selection criteria for choosing between the original brand, generic, and micronized versions of abiraterone.

“The trial was specifically looking at whether that aggressive margin reduction from 4 mm to 2 mm would lead to a reduction in physician-reported urinary toxicity, specifically in the first 90 days ...

This video segment covers patient selection criteria for different versions of abiraterone, strategies for assessing treatment efficacy and safety, engaging caregivers to monitor compliance and side ...

Signati's Separo system achieved FDA de novo market clearance application after demonstrating safety and effectiveness in GLP data and an IDE study. The Separo system enables a transdermal vasectomy, ...

"I think we're learning slowly—I hope faster—how to use these agents as any other drug that a pharmaceutical company would study," says Channing J. Paller, MD. In this video, Channing J. Paller, MD, ...

Urology Coding Q&A: Can G2211 be reported regardless of payer?

Experts discuss the variability of non-muscle invasive bladder cancer (NMIBC) in terms of staging and risk stratification and how they navigate these diagnoses with their patients.